118 Quick summary: This landmark 50 million dollar donation scales up the development of advanced immunotherapy and AI driven early detection models that leverage data from over 50% of the Israeli population. By integrating conventional clinical excellence with holistic and complementary care, the investment empowers the institute to establish a new global standard for whole person cancer medicine. These findings and the resulting clinical breakthroughs will directly influence international healthcare practices, improving long term survival rates and mental well being for patients through more personalised and compassionate treatment pathways. Dr Susan and Dr Henry Samueli Donate $50 Million to the Samueli Integrative Cancer Pioneering Institute at Israel’s Clalit–Beilinson Hospital (Thursday, 30th April, 2026 – Petach Tikvah, Israel) – The Samueli Integrative Cancer Pioneering Institute at Clalit–Beilinson Hospital has received an unprecedented $50 million grant from Dr Susan and Dr Henry Samueli. This marks the couple’s second major contribution to the research institute established at the Davidoff Cancer Centre. The Samuelis stated: “By combining world-class research with holistic, compassionate care, our gift aims to shape a new model of cancer treatment for the benefit of humanity.” In 2022, Dr Henry Samueli, Co-Founder of Broadcom Corporation and Chairman of the Board of Broadcom Inc., one of the world’s leading semiconductor companies, together with Dr Susan Samueli, a philanthropist dedicated to advancing healthcare, decided to support the establishment of a research institute focused on achieving breakthroughs in whole-person cancer medicine. Their initial investment of $25 million in 2023 enabled the establishment of the Institute. In 2024, the Institute inaugurated state-of-the-art GMP laboratories dedicated to the development and production of advanced immunotherapy treatments, with three experimental therapies already being tested in patients. The Institute’s advanced AI centre has unparalleled access to Clalit Health Services’ extensive data repositories, covering more than half of Israel’s population, and develops cutting-edge models for cancer early detection and prediction of clinical outcomes. This patient-centred vision is realised through pioneering integrative research that converges conventional and complementary clinical approaches. Dr Susan and Dr Henry Samueli added: “We believe that Israeli scientific excellence, supported by research funding, can deliver the next major breakthrough in cancer care. Israel has some of the brightest minds and the determination to transform the way cancer is studied and treated. We are confident that this gift will further advance the remarkable research already taking place here and help bring healing to patients in Israel and around the world.” Professor Gal Markel, Director of the Davidoff Cancer Centre and Chair of the Samueli Integrative Cancer Pioneering Institute, by Clalit Health Services, said: “This is a truly historic donation and an inspiring expression of trust in our ability to unite clinicians and scientists. In just three years, our teams have achieved significant international milestones that will shape the future of cancer medicine. The path we are paving will be adopted worldwide, bringing hope and healing. I am deeply moved that the Samuelis have once again chosen to entrust us with this mission.” Professor Eytan Wirtheim, CEO of Clalit Health Services, said: “In recent years, Dr Susan and Dr Henry Samueli have become not only true partners of Rabin Medical Centre–Beilinson Hospital and the Davidoff Cancer Centre, but also the people who enable us to turn dreams into reality and bold ideas into scientific and medical achievements. This unique donation, dedicated exclusively to research, reflects their deep commitment to our shared mission. I thank them for the great privilege of standing together at the forefront of the global fight to eradicate cancer.” Brigadier General (Retd) Avner Paz Tsuk, Chief Executive Officer of the Samueli Integrative Cancer Pioneering Institute, by Clalit Health Services added: “Thanks to our exceptional and dedicated staff, and to this extraordinary gift, the Institute is positioned to become one of the world’s emerging forces in applied cancer research. We will continue to pioneer the future of cancer treatment and early detection, inspiring hope and saving lives.” Dr Erez Barenboim, CEO of Beilinson & Hasharon Hospitals (Rabin Medical Centre), Clalit Health Services, said: “This donation transforms Israel and Beilinson Hospital into a global powerhouse in cancer research and treatment. It strengthens our leadership in medical, scientific, and technological innovation and enables us to change reality for patients in Israel and around the world. I extend my heartfelt thanks to the donors for their trust and partnership in an initiative of national importance.”